TKL Research, Inc.: One-Stop-Shop for Clinical Research in Dermatology
pharmatechoutlook

TKL Research, Inc.: One-Stop-Shop for Clinical Research in Dermatology

Follow TKL Research, Inc on :

Jon C. Anderson, President and CEO, TKL Research, IncJon C. Anderson, President and CEO
 
The past 75 years have brought about a tremendous amount of change. From the introduction of the color TV and the creation of computers to the invention of the World Wide Web and now the smartphone revolution, one thing has remained constant, steady and strong - TKL Research, Inc., a 75-year old full-service CRO. Successfully catering to the pharmaceutical, biotechnology, medical device, and consumer healthcare industries since its inception, TKL firmly stands as one of the pre-eminent CROs in the country.

At the company’s helm for the past 40 years is Dr. Jon C. Anderson. Under his unwavering leadership, he has shaped a company that is anything but average in this time of massive mergers and jumbo CROs. TKL is an integrated network of clinical research centers consisting of a 40-bed pharmacology unit and four outpatient clinics in the NY/NJ metro area. Combining this unique structure with TKL’s seasoned professional staff gives you one of the industry’s most experienced, focused, and flexible CROs.

TKL’s roots are in dermatology. To say that they are experts would be an understatement. Last year alone, TKL conducted over 300 dermatological safety studies, the highest number achieved by any CRO in the market. In addition, TKL has managed over 140 multicenter phase I-III dermatological trials over the past 25 years. “We understand skin better than anybody. Our track record remains unparalleled in the dermatology CRO world,” remarks Anderson.

We understand skin better than anybody and also know how to manage clinical trials

The company has a robust investigator database, which enables it to identify the target patient populations in a variety of dermatologic conditions such as acne, psoriasis, actinic keratosis, atopic dermatitis, and more.

When partnering with a CRO, organizations consider good investigator relationships, enrollment metrics, quality data, experienced and dedicated staff, and sufficient infrastructure. TKL checks all of these boxes. “We become their strategic partners and help them get through the process of evaluating drugs for both safety and efficacy,” adds Anderson. TKL’s comprehensive approach allows clients to carry out both the early and later phases of clinical studies. Those partnering with TKL can go into phase I testing and continue through phase II and beyond. This model proves efficient as the clients can continue to work with the same designated team during all phases of the investigational program.

TKL has clients that speak volumes of the brilliance it brings to the table. One being a biotech company that faced difficulties in getting approval for a transdermal delivery drug from the FDA serves as a testimony to this. The FDA had sent a Complete Response Letter (CRL) to the company and questioned the adherence capacity and manufacturing process of the trans-dermal patch system being developed. TKL’s expert personnel identified the problem and compared the adhesive properties of the sponsor drug with the reference labeled drug available in the market. The comparative studies provided the necessary data and results, addressing the CRL and maintaining the timelines. Upon resolving the issues, TKL helped the company receive FDA approval.

Over the years, TKL has scripted many such success stories, creating giant strides in the pharma space. Furthermore, the company continues to expedite clinical processes by embracing the latest technologies. The NJ-based firm is also aiming to expand its geographical presence outside the country, while continuing to achieve milestones in the years to come.
Share this Article:

Company
TKL Research, Inc

Headquarters
Fair Lawn, NJ

Management
Jon C. Anderson, President and CEO

Description
TKL Research, Inc. is a 75-year old full-service CRO. Successfully catering to the pharmaceutical, biotechnology, medical device, and consumer healthcare industries since its inception, TKL firmly stands as one of the pre-eminent CROs in the country. TKL is an integrated network of clinical research centers consisting of a 40-bed pharmacology unit and four outpatient clinics in the NY/NJ metro area. Combining this unique structure with TKL’s seasoned professional staff gives you one of the industry’s most experienced, focused, and flexible CROs

TKL Research, Inc